Inogen, Inc.
HealthcareNASDAQ:INGN · NASDAQ Global Select
+$0.10 today
Vol 0.15M · Avg 0.33M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$351.5M of revenue converted into -$24.9M of net income for the selected period. Gross margin is 48.8% and net margin is -7.2%, showing how much revenue survives after costs and taxes. EPS is $-0.91, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $348.7M +3.9% | $335.7M +6.4% | $315.7M -16.3% | $377.2M +5.4% | $358.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $182.8M +1.0% | $181.0M -4.2% | $189.0M -15.5% | $223.7M +23.2% | $181.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $165.9M +7.2% | $154.7M +22.1% | $126.7M -17.5% | $153.5M -13.0% | $176.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 47.6% +1.5pp | 46.1% +6.0pp | 40.1% -0.6pp | 40.7% -8.6pp | 49.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $19.4M -10.2% | $21.6M +3.7% | $20.8M -5.0% | $21.9M +32.4% | $16.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $165.1M -6.0% | $175.6M -3.7% | $182.4M +10.7% | $164.7M +9.3% | $150.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $196.1M -0.6% | $197.3M -16.4% | $236.1M -1.1% | $238.8M +42.8% | $167.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $20.7M -1.6% | $21.0M +15.7% | $18.2M -22.8% | $23.5M +8.7% | $21.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$2.7M +82.4% | -$15.5M +73.5% | -$58.3M -509.7% | -$9.6M -131.6% | $30.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -0.8% +3.8pp | -4.6% +13.9pp | -18.5% -15.9pp | -2.5% -11.0pp | 8.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$30.2M +29.0% | -$42.5M +61.1% | -$109.4M -28.3% | -$85.2M -1022.5% | $9.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -8.7% +4.0pp | -12.7% +22.0pp | -34.7% -12.1pp | -22.6% -25.2pp | 2.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.2M -58.5% | $5.2M -21.1% | $6.6M +131.7% | $2.8M +2099.2% | $129.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $6.8M +13.0% | $6.0M -14.2% | $7.0M +256.6% | $2.0M +439.9% | -$581.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$23.4M +35.9% | -$36.5M +64.4% | -$102.3M -22.9% | -$83.3M -1061.6% | $8.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -6.7% +4.2pp | -10.9% +21.6pp | -32.4% -10.3pp | -22.1% -24.5pp | 2.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$632.0K -7.5% | -$588.0K -660.0% | $105.0K -79.2% | $504.0K -96.6% | $15.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$22.7M +36.6% | -$35.9M +65.0% | -$102.4M -22.3% | -$83.8M -1222.8% | -$6.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | -6.5% +4.2pp | -10.7% +21.8pp | -32.5% -10.2pp | -22.2% -20.4pp | -1.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +44.1% | -$2 +65.6% | -$4 -20.4% | -$4 -1210.7% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +44.1% | -$2 +65.6% | -$4 -20.4% | -$4 -1210.7% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $27.2M +14.9% | $23.7M +2.1% | $23.2M +1.4% | $22.9M +1.6% | $22.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $27.2M +14.9% | $23.7M +2.1% | $23.2M +1.4% | $22.9M +1.6% | $22.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Shoulder Innovations, Inc.
NYSE:SI
$387.80M
Sight Sciences, Inc.
NASDAQ:SGHT
$279.12M
Perspective Therapeutics, Inc.
AMEX:CATX
$227.89M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Quanterix Corporation
NASDAQ:QTRX
$146.03M
Health Catalyst, Inc.
NASDAQ:HCAT
$136.70M
SANUWAVE Health, Inc.
NASDAQ:SNWV
$128.21M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
Solana Company
NASDAQ:HSDT
$89.92M
Outset Medical, Inc.
NASDAQ:OM
$83.23M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does INGN generate?
Inogen, Inc. (INGN) reported $348.67M of revenue in fiscal 2025.
Is INGN profitable?
Inogen, Inc. (INGN) reported -$22,747,000.00 of net income, with a net margin of -6.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.